VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection (AIR). The strategy utilizes a proprietary tumor-specific, tumor-type agnostic, virus-inspired platform termed Anti-tumor Immune Redirecting Virus-inspired Particles (AIR-ViP™) that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. This unique mechanism of action allows differentiation within the competitive Immuno-Oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have un-treatable cancers due to limited options or resistance.
VerImmune has already obtained superb in vitro and in vivo animal model data addressing safety, mechanism of action and efficacy of the approach and has established a scientific advisory board with world-class KOLs. It is now developing a broad pipeline with initial products covering up to 70% of patients with solid tumors.
VerImmune has raised $1.5M seed round and is now looking to additionally raise $14M to advance the development of the lead product candidate, VERI-101 (CMV-AIR) to an IND to allow its first-in-human clinical studies. We would welcome the opportunity to discuss the AIR technology platform, product candidates and plans in more detail at your earliest convenience. Please feel free to email us at info@verimmune.com
VerImmune has already obtained superb in vitro and in vivo animal model data addressing safety, mechanism of action and efficacy of the approach and has established a scientific advisory board with world-class KOLs. It is now developing a broad pipeline with initial products covering up to 70% of patients with solid tumors.
VerImmune has raised $1.5M seed round and is now looking to additionally raise $14M to advance the development of the lead product candidate, VERI-101 (CMV-AIR) to an IND to allow its first-in-human clinical studies. We would welcome the opportunity to discuss the AIR technology platform, product candidates and plans in more detail at your earliest convenience. Please feel free to email us at info@verimmune.com
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Oncology
Lead Product in Development:
CMV Anti-tumor Immune Redirector
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speakers
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
